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Abstract: Acne is a common disorder affecting the majority of adolescents and often extends 
into adulthood. The central pathophysiological feature of acne is increased androgenic stimula-
tion and/or end-organ sensitivity of pilosebaceous units leading to sebum hypersecretion and 
infundibular hyperkeratinization. These events lead to Propionibacterium acnes proliferation 
and subsequent inflammation. Hormonal therapy, including combined oral contraceptives (OCs), 
can attenuate the proximate androgenic trigger of this sequence. For many women, hormonal 
therapy is a rational option for acne treatment as it may be useful across the spectrum of severity. 
Drospirenone (DRSP) is a unique progestin structurally related to spironolactone with proges-
togenic, antimineralocorticoid, and antiandrogenic properties. It is available in 2 combined OC 
preparations (30 µg EE/3 mg DRSP; Yasmin® in a 21/7 regimen; and 20 µg EE/3 mg DRSP; 
Yaz® in a 24/4 regimen). These preparations are bereft of the fluid retentional side effects typical 
of other progestins and their safety has been demonstrated in large epidemiological studies in 
which no increased risk of vascular thromboembolic disease or arrhythmias was observed. In 
acne, the efficacy of DRSP-containing OCs has been shown in placebo-controlled superiority 
trials and in active-comparator non-inferiority trials.
Keywords: acne vulgaris, combined oral contraceptives, drosperinone, ethinyl estradiol, 
efficacy, safety, treatment
Introduction
Acne vulgaris is a common condition affecting up to 93% of adolescents and teens1,2 
and can persist into adulthood in 53% of women and 40% of men.3,4 Women are more 
likely to report having acne and to have it persist into later years with a mean duration 
in affected adult women of 20 years.5
Due to involvement of visible anatomical sites such as the face and upper torso, 
along with the potential for chronicity, acne has been associated with a wide spectrum 
of psychological and social dysfunction including depression, anxiety, suicidal ideation, 
somatization, embarrassment, and social inhibition.6–8 In particular, adult women have   
been shown to be adversely impacted by the effect of acne on their quality of life.9
Hormonal therapies, including those with and without oral contraceptive (OC) 
properties, have been used by dermatologists as a treatment for acne vulgaris for over 
4 decades. For many women, the use of hormonal therapy is a rational option for acne 
treatment as they may be used across the spectrum of severity. OCs may be used for 
mild acne in women desiring a form of contraception, and in moderate acne as a pri-
mary form of therapy. In severe acne, they are frequently used as one of 2 prerequisite 
forms of contraception for those initiating oral isotretinoin.10International Journal of Women’s Health 2009:1 214
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The non-contraceptive hormonal options include 
spironolactone, cyproterone and flutamide.11 Of these, 
spironolactone – a synthetic steroid which binds to androgen 
receptors, inhibits 5 alpha-reductase activity, and reduces 
androgen biosynthesis – has been used for over 3 decades in 
the treatment of acne and has a long record of safety.12 Prior to 
the current era of evidence-based medicine, experiential sup-
port suggested the efficacy and relative safety of these agents. 
Since then, OCs have evolved to contain less estrogen, thereby 
enhancing their safety and tolerability profile, and to include 
progestins with low or antiandrogenic potential to improve 
efficacy in acne. Furthermore, the past decade has witnessed 
an increase in quality of evidence to support the use of these 
agents in treatment of acne. Based on clinical trial evidence, 
the United States Food and Drug Administration (FDA) has 
approved the following combined OC preparations for treat-
ment of moderate acne: ethinyl estradiol (EE) 20/30/35 µg 
plus norethindrone 1 mg (Estrostep Fe®; Warner-Chilcott), EE 
35 µg plus norgestimate 180/215/250 µg (Ortho Tri-Cyclen®; 
Janssen-Ortho), and EE 20 µg plus drospirenone 3 mg (Yaz®; 
Bayer). In Canada, the corresponding list approved by Health 
Canada also includes EE 35 µg/cyproterone acetate 2 mg 
(Diane-35®; Bayer; not officially indicated in Canada as 
an OC), EE 20 µg/levonorgestrel 100 µg (Alesse®; Wyeth 
Pharmaceuticals), and EE 35 µg/drospirenone 3 mg (Yasmin®; 
Bayer). The most recently approved of these are OCs in which 
the progestin component is drosperinone (DRSP), a derivative 
of spironolactone. This review focuses on the evidence sup-
porting the use of these agents in the treatment of acne.
Acne pathogenesis and hormonal 
treatment
The pathogenesis of acne is conceptualized to involve androgen-
stimulated hyperkeratinization of the follicular infundibulum 
and sebaceous hypersecretion; Propionibacterium acnes 
proliferation within the anaerobic milieu of the pilosebaceous 
duct, and subsequent inflammation. Effective treatments would 
ideally target multiple pathogenic factors simultaneously and/or 
abrogate the initiating event such as androgenic stimulation 
of pilosebaceous structures.13 While each of these modalities 
targets specific distal pathogenic factor(s), only hormonal 
therapy ameliorates proximate androgenic stimulation.
Mechanism of action of combined 
OCs in acne
Combined OCs are comprised of estrogenic and proges-
togenic components. Their antiandrogenic potential in 
acne results from a variety of mechanisms (see Figure 1). 
Suppression of pituitary gonadotrophin secretion reduces 
androgen production by the ovaries. Additionally, com-
bined OCs directly inhibit androgenesis by the ovaries and 
adrenal glands.14 The estrogenic component of these agents 
increase hepatic production of sex hormone binding globulin 
(SHBG) which binds to testosterone, thereby reducing lev-
els of bioavailable testosterone. The progestin component 
inhibits 5-α reductase activity, reducing the conversion of 
testosterone at end-organs to the more biologically potent 
dihydrotestosterone (DHT). Furthermore, some progestins 
act as inhibitors to DHT and other androgens by competitive 
binding to androgen receptors.14 Recent studies have shown 
that androgen receptors can be found at the basal layer of 
sebaceous glands of the skin and that skin and sebaceous 
glands contain the biochemical substrates for androgen 
production and metabolism. Major isozymes of steroid 
metabolizing enzymes can be found in human sebaceous 
glands and androgens can be produced within them from 
adrenal-derived dehydroepiandrosterone sulfate.15 Accord-
ingly, the antiandrogenic effects of some progestins may 
also be mediated locally by inhibiting autocrine stimulation 
of sebaceous glands by androgens.
Pharmacology of drosperinone
Drosperinone (6β,7β,15β,16β-dimethylene-3-oxo 17α-
pregn-4-ene-21,17 carbolactone), an analog of spironolactone, 
is a synthetic progestin uniquely combining progestogenic 
activity with antimineralocorticoid and antiandrogenic 
properties.16–18 It is the only progestin currently available 
that it is neither derived from 17α-acetoxyprogesterone nor 
19-nortestosterone and is thus devoid of androgenic effects of 
the latter. While comprehensive reviews of the pharmacology 
of DRSP are available elsewhere,19–21 this section focuses on 
features salient to clinicians.
The progestogenic potency of DRSP has been studied 
in several animal models where it was found to be within 
the potency range of cyproterone acetate and norethisterone 
acetate.16 In humans, DRSP been shown to have strong central 
and peripheral progestational activity17 rendering it suitable 
for oral contraception and hormonal replacement therapy. 
Additionally, no drug interactions were noted between 
DRSP and EE that would interfere with the progestogenic 
or antimineralocorticoid activity of DRSP.16
In healthy women, estrogen activates the renin-angiotensin 
system with attendant effects on sodium and fluid reten-
tion. In contrast, progesterone antagonizes some of these 
aldosterone-mediated effects by high affinity binding International Journal of Women’s Health 2009:1 215
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to the mineralocorticoid receptor. DRSP shares the 
antimineralocorticoid properties of progesterone and its 
parent compound spironolactone. Compared to spirono-
lactone, the antimineralocorticoid potency of DRSP is 
approximately eight-fold higher.22 Thus, the antimineralo-
corticoid effect of 3 mg DRSP is equipotent to 25 mg of 
spironolactone. The absence of antimineralocorticoid activity 
with other progestins may contribute to fluid retention 
with associated features of weight gain, breast tenderness, 
nausea, headache and hypertension.21 Therefore, DRSP may 
ameliorate certain estrogen-induced side effects in women 
taking OCs. Their use, however, is attended by warnings 
regarding patients at risk of hyperkalemia including renal 
insufficiency, hepatic dysfunction, adrenal insufficiency, and 
in those taking medications affecting potassium levels and 
the renin-angiotensin system (ACE inhibitors, angiotensin II 
receptor antagonists, K-sparing diuretics, K supplementation, 
aldosterone antagonists, and non-steroidal anti-inflammatory 
agents).23
DRSP is antiandrogenic, inhibiting androgen receptor-
mediated transcription in a dose dependent manner.19 
In vivo experiments of antiandrogenic potency by inhibi-
tion of testosterone-induced prostatic growth in juvenile 
castrated male rats have shown that DRSP has a potency 
almost ten times greater than progesterone;19 one-third that 
of cyproterone; but superior to that of spironolactone.16,21 
The antiandrogenic dose equivalency for DRSP compared 
to spironolactone is undetermined.
The oral bioavailability of DRSP is ∼76% and peak 
plasma levels are attained in 1-2 hrs. Serum half-life is DRSP 
is ∼31 hours, while that of EE is 24 hours. Approximately 
45% of an oral dose of DRSP is excreted in the urine and 
20% in feces. While it is not bound to SHBG, up to 97% is 
loosely bound to serum albumin.24
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Figure 1 Androgens in acne pathogenesis and the countervailing effects of combined oral contraceptives (OCs) and antiandrogens. Gonadotropin stimulation of ovaries 
leads to increased androgenesis. Testosterone is derived from ovarian and adrenal glands. Sex hormone binding globulin (SHBG) binds to testosterone thereby reducing the 
fraction available for biological activity. Conversion of testosterone to dihydrotestosterone (DHT), the more potent tissue-active metabolite, is mediated by 5α reductase 
in tissues. DHT increases sebum excretion from sebaceous glands and induces epidermal hyperkeratinization at the infundibulum of pilosebaceous units. These events lead 
to the formation of comedones. Subsequent proliferation of P. acnes bacteria leads to inflammation, manifested as inflammatory lesions of acne. Combined OCs act to block 
certain portions of the androgenic pathway (X) and enhance SHBG production (+). Antiandrogens, including DrSP, induce androgen receptor blockade at relevant tissue 
sites (I).International Journal of Women’s Health 2009:1 216
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Clinical trials of EE/DRSP OCs 
in acne
While more than 25 outcome measures have been used in 
acne studies,25 most have not been evaluated for accuracy 
or reproducibility. Since the 1980s, however, the Center 
of Drug Evaluation and Research (CDER) of the FDA 
approval of new acne treatments has required demonstration 
of statistically significant superiority in two of three acne 
lesion count measures (non-inflammatory, inflammatory or 
total counts) and in static investigator global assessments 
(IGA).26 This approach is based on the clinical relevance 
of global assessments given the pleomorphic presentation 
of acne, with varying types of primary lesions in extent 
and distribution; combined with the greater objectivity and 
morphologic specificity of lesion counting. Primary lesions 
in acne are divided into non-inflammatory (comedonal) and 
inflammatory (papules, pustules, nodules) lesions, while 
total counts are a summation of these two types. Secondary 
lesions, which are excluded from primary lesion counting and 
IGA, comprise post-inflammatory erythema, dyspigmenta-
tion and scarring.27
At present, DRSP is only available in 2 OC prepara-
tions combined with EE (30 µg EE/3 mg DRSP; Yasmin® 
in a conventional 21-day hormone/7-day inert regimen; 
and 20 µg EE/3 mg DRSP; Yaz® in a 24/4 regimen). The 
24 day hormone and 4 day hormone-free interval regimen 
was developed for 20 µg EE/3 mg DRSP in recognition of 
the greater contraceptive margin of safety with a shorter 
hormone free interval for low-dose combined OCs.28 In this 
section, we evaluate the evidence supporting the use of these 
agents in treatment of acne based on placebo-controlled 
and active-comparator clinical trials.
Placebo-controlled trials
Two placebo-controlled randomized trials of identical 
design have been performed for 20 µg EE/3 mg DRSP 
(20EE/DRSP) over 6 cycles.29,30 While 2 other publications 
are cited in the literature,31,32 they are both based on the same 
datasets and analyses as those reported in Maloney et al29 
and Koltun et al30 respectively. Accordingly, they will not 
be discussed further herein. No placebo-controlled trials for 
30 µg EE/3 mg DRSP (30EE/DRSP) have been published 
for this indication.
Inclusion criteria in both studies were healthy females 
aged 14 to 45 years; at least moderate facial acne severity; 
minimum of 20 inflammatory papules and/or pustules and 20 
noninflammatory lesions. Of note is that these acne-specific 
criteria requested by the FDA were amendments that had 
originally had greater range of lesion numbers and a severity 
spectrum that extended to also include mild acne. As these 
amendments occurred after recruitment, the total number 
of patients in both trials was greater than that undergoing 
final efficacy analysis. The IGA was a static scale, not 
referenced to baseline severity, and based on 6 categories 
ranging from 0 (normal clear skin) to 5 (many inflamma-
tory and noninflammatory acne lesions). Successful IGA 
outcomes were the attainment of clear (0) and almost clear 
(1) severity categories. Exclusion criteria included typical 
contraindications for combined oral contraceptive use and 
other acne treatments.
For each study, a sample size of 250 per group was calcu-
lated to provide a power of 90% to detect group differences. 
Based on the amended criteria, however, the population 
available for analysis were 218 in the 20EE/DRSP group 
and 213 in the placebo group in one study29 and 228 and 
230, respectively, in the other.30 Thus, each of these studies 
did not achieve the recruitment target based on the power 
calculation.
Baseline demographics for subjects in both groups in 
each study were similar. Significant improvements for the 
20EE/DRSP groups at end of study were demonstrated for 
all efficacy outcome measures (see Table 1). Weighted data 
pooling (see Table 2) for number of subjects from these tri-
als demonstrated the following significant improvements in 
the active treatment group: 49% for inflammatory lesions 
(placebo 33%); 40% for noninflammatory lesions (placebo 
22%), and 44% for total lesions (placebo 28%), 18% achiev-
ing IGA success of clear/almost clear (placebo 6%).
Adverse events in both trials were characteristic of low-
dose combined oral contraceptive therapy and largely mild to 
moderate in intensity. A greater proportion of subjects in the 
active arm reported metrorrhagia, menorrhagia, and breast 
pain. In the active treatment arm of both studies, 2 serious 
adverse events (depression, pneumonia) were reported but 
were not considered attributable to study medication. A total 
of 8 pregnancies in the active treatment arms were reported. 
Details on 4 were available –2 pregnancies were prior to 
study medication intake, and 1 was due to non-compliance.29 
No significant differences in blood pressure or serum potas-
sium levels were observed in either trial between active and 
placebo groups.
These 2 studies provide the highest level evidence for the 
efficacy of  20EE/DRSP in treatment of at least moderate facial 
acne over 6 cycles. Furthermore, the significant improve-
ments in lesion counts and achievement of global success in 
acne grading were clinically relevant. Shortcomings of these International Journal of Women’s Health 2009:1 217
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studies include inadequate stratification baseline severity 
based on IGA and inadequate data on pregnancies in 
1 study.30
Active-comparator trials
Two active-comparator trials in acne for 30EE/DRSP have 
been performed, both with a non-inferiority design. Such trials 
differ methodologically from the more typical superiority 
design. A primary consideration in such studies is that the effi-
cacy of the comparator is established or is used widely such 
that a placebo design would be considered unethical. In con-
trast to superiority trials, the null hypothesis in non-inferiority 
trials is that the treatments differ by a pre-established margin. 
The pre-stated margins of non-inferiority can be established 
as the smallest value representing a clinically relevant effect 
or a value smaller than the effect chosen to investigate supe-
riority over placebo. With non-inferiority trials, type I error 
reflects incorrect acceptance of an inferior new treatment and 
type II error is incorrect rejection of a non-inferior treatment. 
Lastly, analysis of per-protocol groups rather than intent to 
treat as in superiority trials reduces the risk of type I error 
in non-inferiority trials.33 No active-comparator trials are 
available for 20EE/DRSP to date.
Comparison to 35 µg ethinyl 
estradiol/2 mg cyproterone acetate34
The efficacy of  30EE/DRSP versus 35 µg ethinyl estra-
diol/2 mg cyproterone acetate (EE/CPA) was evaluated in 
an active-comparator trial with non-inferiority design. This 
9-cycle double-blind randomized controlled trial had the 
following inclusion criteria: women 16 to 35 years, mild-to-
moderate facial acne, and a minimum of 8 papulo-pustules. 
Standard exclusion criteria regarding contraindications for 
combined OC use and acne treatments applied.
The primary efficacy outcome was the change in total 
acne lesion count from baseline to end of study at the 9th 
cycle. The null hypothesis, that 30EE/DRSP was inferior to 
EE/CPA relative to change in total acne lesion counts, was 
tested against the alternative hypothesis of non-inferiority 
with a margin of 25%.
One hundred and twenty-eight women were recruited 
and randomized in a 2:1 ratio to receive 30EE/DRSP or EE/
CPA, respectively. Baseline demographics between groups 
were similar. The intent to treat (ITT) population comprised 
subjects who had taken trial medication at least once (total 
N = 125; 30EE/DRSP, 82 and EE/CPA, 43). Of these, those 
who completed the study without major protocol violations 
comprised the per protocol (PP) population (total N = 91; 
30EE/DRSP, 58, EE/CPA, 33).
In  the  PP  population,  mean  total  lesion  count 
reductions were 46.8% (SD ± 42.2) for 30EE/DRSP and 
40.4% (SD ± 70.2) for EE/CPA. In both ITT and PP datasets 
30EE/DRSP was found to be noninferior to EE/CPA after 
9 cycles (P = 0.0006). Non-inflammatory lesion counts were 
reduced by 50% (from mean of 23 to 9) and 60% (from 
21 to 6) in the 30EE/DRSP and EE/CPA groups respectively. 
Corresponding reduction in inflammatory lesion counts 
(papules and pustules) were 73.5% (from 16 to 4) and 75% 
(from 20 to 5) respectively.
One serious adverse event (shoulder-arm syndrome) 
was reported in the 30EE/DRSP group, but was considered 
unrelated to treatment. Both preparations were well tolerated 
and adverse events typical of low-dose combined oral con-
traceptive therapy were largely mild-to-moderate in severity 
Table 1 Efficacy results of 20 µg EE/3 mg DRSP vs placebo trials in acne
Treatment arm Maloney et al29 Koltun et al30
Active Placebo Active Placebo
N 218 213 228 230
OUTCOMES*
IGA success  
(clear or almost clear)
21%
(46)
9%
(19)
15%
(35)
4%
(10)
% reduction total lesions  
(baseline absolute mean)
46%
(76)
31%
(76)
42%
(80)
25%
(80)
% reduction inflammatory lesions  
(baseline absolute mean)
51%
(32)
34%
(32)
48%
(33)
32%
(33)
% reduction noninflammatory lesions   
(baseline absolute mean)
42%
(44)
26%
(44)
39%
(47)
18%
(47)
*P values for all outcomes 0.001 versus placebo.International Journal of Women’s Health 2009:1 218
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and similar in both groups. No clinically significant changes 
in heart rate, blood pressure, or laboratory parameters were 
noted in either group. Weight gain was observed in 2.4% 
of those on 30EE/DRSP and 9.3% on EE/CPA. Breast pain 
was less frequently reported in the 30EE/DRSP group: 8.5% 
compared to 16.3% on EE/CPA.
This study showed that 30EE/DRSP was non-inferior to 
EE/CPA over 9 cycles in total acne lesion count reduction, 
with a non-inferiority margin of 25%. There are, however, 
methodological issues with this study. It is unclear how the 
non-inferiority margin of 25% was determined. Previous 
placebo-controlled trials of other combined OCs have 
found a significant difference in total lesion counts after 
6 cycles of 15% to 20%.35–38 Accordingly, a non-inferiority 
margin beyond this range would be considered excessive. 
Of additional concern is that no information is provided 
on the power of the study or the related determination of 
sample size. Furthermore, the clinically relevant measure 
of global assessment grading was not used in this study. 
Since clinicians typically use global assessments in clinical 
practice rather than lesion counts, the generalizability of 
these results is limited.
Comparison to a triphasic preparation 
containing 35 µg ethinyl estradiol 
and norgestimate39
The triphasic preparation 35 µg EE/0.180, 0.215, 0.250 mg 
norgestimate (EE/NGM; Pramino®, Ortho Tri-Cyclen®) 
has previously been demonstrated in 2 placebo-controlled, 
double-blind randomized trials to be effective in treatment 
of moderate facial acne.35,36
Designed in a similar manner to these studies, a compara-
tor study of 30EE/DRSP with EE/NGM was randomized, 
prospective, and double-blinded with the same inclusion 
criteria. Specifically, these comprised healthy females aged 
15 to 40 years with mild to moderate facial acne vulgaris 
and no contraindications to combined oral contraceptive use. 
Subjects were required to have 6 to 100 non-inflammatory 
lesions, 10 to 50 papules and/or pustules, and less than 
5 nodules. However, unlike the superiority design of the 
earlier placebo-controlled studies, this study was designed 
as a non-inferiority trial. Participants were randomized in a 
1:1 ratio to 30EE/DRSP or EE/NGM for 6 treatment cycles. 
Efficacy outcomes included lesion counts and retrospec-
tive investigator assessments of therapeutic effect based on 
recall of baseline severity. A static global assessment was 
not performed.
This study tested the hypothesis that EE/DRSP was non-
inferior by a margin of 10% to EE/NGM at improving the 
lesion counts and proportion of subjects with improvement 
based on investigator assessment. The calculated minimum 
sample size for the each of the primary variables based on 
power of 90% and a one-sided significance level of 2.5% 
was 338 for each treatment group.
A total of 1154 subjects were randomized to either 30EE/
DRSP (n = 568) or EE/NGM (n = 586) groups. Of these, 566 
assigned to 30EE/DRSP and 582 to EE/NGM comprised 
the ITT group while 486 in the 30EE/DRSP and 505 in the 
EE/NGM were included in the PP group. For the purpose 
of non-inferiority analysis, the PP group was subjected to 
further evaluation while the ITT group was used for analysis 
of superiority.
In the PP group, mean inflammatory lesion counts 
were reduced by 76% (SD ± 26) and 72% (SD ± 28) in the 
30EE/DRSP and EE/NGM groups respectively after 6 cycles. 
Total lesion counts were reduced by 68% (SD ± 24) in the 
EE/DRSP group and 65% (SD ± 26) in the EE/NGM group 
after 6 cycles. These differences in favor of 30EE/DRSP 
(3%) demonstrated non-inferiority to EE/NGM at the 10% 
level for total and inflammatory lesion counts. On analysis 
with the ITT population, these differences were shown to 
be significant compared to EE/NGM (95% CI, –6.5 to –0.1; 
P = 0.020). Investigators assessment of acne improvement 
based on comparison to baseline demonstrated that 97% 
on 30EE/DRSP compared to 94% on EE/NGM showed 
improvement in facial acne. This difference of 3% was within 
the non-inferiority margin of 10% and significantly favored 
30EE/DRSP (95% CI, 0.8 to 6.3; P = 0.006).
Adverse events related to treatment were mostly of mild 
or moderate intensity and did not cause discontinuation of 
treatment. Those events reported by over 2% of subjects in 
the 30EE/DRSP and EE/NGM groups were typical of other 
combined oral contraceptives and included nausea (4.8% vs 
5.5%), headache (3.9% vs 3.6%), breast pain (2.8% vs 2.9%), 
and abdominal pain (1.4% vs 2.2%). No significant changes 
Table 2 Pooled outcomes of 20 µg EE/3 mg DRSP vs placebo trials 
in acne29,30
Outcome Pooled results
   Active Placebo
pooled IGA success 18% 6%
% reduction total lesions 44% 28%
% reduction inflammatory lesions 49% 33%
% reduction noninflammatory lesions 40% 22%
Note: data pooling weighted for number of subjects.International Journal of Women’s Health 2009:1 219
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were reported in safety laboratory parameters, physical and 
gynecological examination, or vital signs. No serious treat-
ment-related adverse events were reported in the 30EE/DRSP 
group, while there were 2 serious adverse events in the 
EE/NGM group considered to be possibly related to treatment 
(migraine and fibrocystic breast). Of the 2 pregnancies in this 
study, 1 subject in the 30EE/DRSP group became pregnant 
during the trial after discontinuing study medication, while 
another subject in the EE/NGM group became pregnant due 
to poor treatment compliance.
This large study was adequately powered to demon-
strate noninferiority of 30EE/DRSP compared to EE/NGM 
with respect to lesion counts and retrospective investigator 
assessment with a margin of 10%. While 30EE/DRSP was 
also shown to be statistically superior to EE/NGM in reduc-
tion of total lesions (3.3%) and retrospective investigator 
assessments (3.6%), the magnitude of these differences is not 
likely to be clinically relevant. A shortcoming of this study 
is the use of an investigator assessment referencing baseline 
severity. Such an outcome measure is flawed by recall bias 
and the potential use of lesion counts to determine clinical 
improvement. The latter would relegate this pivotal clinical 
measure to that of a dependent variable rather than maintain-
ing its role as an independent efficacy outcome.
Trials on safety
The evaluation of thromboembolic risk for combined OCs 
requires many more subjects than typically available in 
smaller efficacy studies in acne. For this class of agents, the 
potential for hyperkalemia due to the antimineralocorticoid 
activity of DRSP and potential for arrhythmias has also been 
of concern. Accordingly, the safety of DRSP-containing OCs 
has been further scrutinized in mandated large post-marketing 
surveillance studies.
Two large studies have been conducted to evaluate the 
risk of vascular thromboembolic disease for 30EE/DRSP 
compared to other OCs.40,41 In a United States population 
using a claims database maintained by United Health Care, 
the incidence of venous thromboembolism (VTE) was evalu-
ated for 22,429 women initiating 30EE/DRSP and a matched 
group of 44,858 initiating other OCs.40 The average duration 
of follow-up was 7.8 and 7.5 months, respectively. VTE was 
confirmed in 18 cases of 30EE/DRSP users and in 39 using 
other OCs. This translated to VTE incidence rates of 1.3/1000 
woman years for those on 30EE/DRSP and 1.4/1000 woman 
years for those on other OCs. The VTE subgroups of deep 
vein thrombosis and pulmonary embolism were equal in 
frequency between these 2 groups.
An European prospective trial of initiators of DRSP 
compared to levonorgestrel and other progestin-containing 
OCs, observed that the incidence of both venous and arte-
rial thromboembolic events did not differ significantly 
between groups. This study comprised 58,674 women 
followed for 142,475 women-years and demonstrated that 
VTE hazard ratios for DRSP-containing versus LNG-
containing OCs and other OCs were 1.0 and 0.7 (upper 
95% CI, 1.8 and 1.3, respectively). Corresponding values 
for arterial thromboembolism were 0.3 and 0.3 (upper 95% 
CI, 1.2 and 1.5, respectively).41 Arrhythmias suggestive of 
hyperkalemia were rare in both groups with an incidence 
was 0.28/1000 woman years for those on 30EE/DRSP com-
pared to 0.26/1000 woman years for those in the comparator 
group. Thus, these studies demonstrated no increased risk of 
vascular thromboembolic disease or arrhythmias for DRSP-
containing OCs.
Summary
DRSP is currently only available with ethinyl estradiol as a 
combined OC in one of 2 preparations varying in dose of EE 
and in duration of hormone/hormone-free intervals: 30 µg 
EE/3 mg DRSP in a 21/7 regimen and a 20 µg EE/3 mg 
DRSP in a 24/4 regimen. In treatment of acne, these agents 
address the androgenic factors operative in acne pathogen-
esis while also providing reliable contraception. The unique 
advantage of DRSP as the progestin in such preparations 
lies in its antimineralocorticoid and antiandrogenic effects. 
They are particularly well tolerated, being devoid of the 
fluid retentional effects of OCs containing other progestins. 
Additionally, their relative safety has been demonstrated in 
large epidemiological surveillance studies.
The theoretical benefits of the antiandrogenic potential 
of DRSP-containing OCs in acne have been recently dem-
onstrated in both placebo-controlled superiority and active-
comparator non-inferiority trials. Additionally, the superiority 
of 30EE/DRSP over EE/NGM (another OC approved for use 
in acne) in acne has been demonstrated statistically. While 
the difference in outcomes favoring 30EE/DRSP was of 
marginal clinical relevance, this is one of the only available 
trials demonstrating the superiority of one OC preparation 
over another in the treatment of acne. Future comparative 
evaluations of OC preparations would assist clinicians in 
selection of acne treatment within this class of agents.
For management of mild to moderate acne in women, OCs 
will likely be used with topical medications such as retinoids 
and antibacterial agents in standard clinical practice. Such 
combination therapy should lead to more rapid onset of effect International Journal of Women’s Health 2009:1 220
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and greater magnitude of improvement given the synergistic 
mechanisms of these different treatments. Future studies 
should evaluate the outcomes of such combination therapy as 
it is more reflective of clinical practice. Additionally, inves-
tigations regarding the antiandrogenic dose equivalency of 
DRSP to spironolactone are especially pertinent in view of 
the widespread use of the latter in treatment of acne. In severe 
acne, the use of DRSP-containing OCs may reduce the risk 
of additional adverse events associated with other combined 
OCs in women requiring contraception when prescribed oral 
isotretinoin. In conclusion, across the spectrum of clinical 
acne severity, the availability of DRSP-containing OCs with 
demonstrated efficacy in acne along with their excellent 
tolerability and safety profiles suggest that they should be 
considered to be the current standards of hormonal therapy 
for women with acne.
Abbreviations
OC, oral contraceptive; EE, ethinyl estradiol; DRSP, dros-
perinone; DHT, dihydrotestosterone; SHBG, sex hormone 
binding globulin; CDER, Center of Drug Evaluation and 
Research; IGA, investigator global assessments; 20EE/DRSP, 
20 µg EE/3 mg DRSP; 30EE/DRSP, 30 µg EE/3 mg DRSP; 
EE/CPA, 35 µg ethinyl estradiol/2 mg cyproterone acetate; 
EE/NGM, triphasic preparation 35 µg EE/0.180, 0.215, 
0.250 mg norgestimate; VTE, venous thromboembolism.
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